ICYMI: New ADORING trial data show high EASI 75 and vIGA-AD response rates with tapinarof cream.
Linda Stein Gold, MD, explains what that means:
HCPLive
@HCPLiveNews
Everything you need to enhance your clinical approach to improving patient care.
- RESOLVE-Lung (phase 2): namilumab, an anti-GM-CSF antibody, missed its primary endpoint in chronic pulmonary sarcoidosis. Rescue events occurred more often with namilumab than placebo. Open-label phase halted early after review. hcplive.com/view/namilumab… #PulmonarySarcoidosis
- In a recent interview with Marc Bonaca, MD, MPH, the executive director of CPC Clinical Research, he discussed the VESALIUS-CV trial and what it means for cardiovascular disease prevention beyond patients with past cardiovascular events. Watch now: hcplive.com/view/vesalius-…
- Specialists can help close vaccination gaps by reviewing COVID-19, flu, and RSV status at every visit. Learn more about what Juanita Mora, MD, had to say about it now. @LungAssociation View: hcplive.com/view/ala-why-c…
- Crisis-free isn't the end of the story. What's still unknown about long-term outcomes after sickle cell gene therapy. https://www.hcplive/com/view/after-sickle-cell-gene-therapy-what-comes-next-
Get the full app experience
Unlock more features and see what people are talking about right now.